Smithkline Beecham Corporation

Glaxosmithkline LLC

Glaxosmithkline Intellectual Property Development Limited

Other

Smithkline Beechman Corporation

Novartis Ag

Jerry Leroy Adams

Jeffrey Charles Boehm

Timothy Francis Gallagher

Ralph F Hall

Ravi Shanker Garigipati

John C Lee

Domingos J Silva

John J Taggart

Dennis Lee

Jiri Kasparec

Joseph Sisko

Irennegbe Kelly Osifo

Paul E Bender

Peter R Young

Qi Jin

John Richard White

Peter C McDonnell

James E Strickler

Dean E McNulty

John Richard Heys

David W Green

Neil W Johnson

Peter William Sheldrake

Don Edgar Griswold

Susan Mary Thompson

Yiqian Lian

Zhi-Qiang Peng

David C Underwood

Michael J Bower

Margaret E Sorenson

John G Gleason

Dashyant Dhanak

Deborah Lynne Bryan

Jun Tang

Carl D Perchonock

Nabil Hanna

Ruth Judik Mayer

Hong Lin

John F Newton

Thomas H Faitg

Xin Peng

Ravishanker Garigipati

Zhi Qiang Peng

John Cheung-Lun Lee

Kenneth Allen Newlander

Kevin J Duffy

Alex Gregory Waterson

Dirk Andries Heerding

Brian W Metcalf

Scott Howard Dickerson

Xinrong Tian

Shinichiro Matsunaga

Jeffrey Michael Axten

Nicholas D Adams

Catherine C K Yuan

Cynthia A Parrish

George Adjabeng

James David Winkler

Scott A Long

John Stellwagen

Tara Renae Rheault

David Edward Uehling

Kevin Kuntz

Hideyuki Sato

Susan B Dillon

Brian Wilson

Martha A Sarpong

Amita M Chaudhari

Yasushi Miyazaki

Yanhong Feng

Keith Hornberger

Yutaka Maeda

Kazys A Razgaitis

Toshihiro Hamajima

Marcus Semones

Kimberly Petrov

Jeffrey M Ralph

Ren Xie

Calvin O Manning

Ravi Shunker Garigipati

George L Seibel

Timothy G Gallagher

Masato Nakano

Jean-Philippe Rocher

Jeffrey H Murray

Sandra D Griego

Gregory Schaaf

Mark Mellinger

Kasparec Jiri

A compound of Formula (I) wherein Y, Y, X, X, R, R, R, R, R, R, R, and Rare as defined herein;and pharmaceutically acceptable salts and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases in which modulation of STING (Stimulator of Interferon Genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer, pre-cancerous syndromes and as vaccine adjuvants.

Compounds

The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R, R, R, R, R, R, Q, Z, and p are as described herein. Compounds of the present invention are useful for the treatment of cancers.

Pyrazolylaminopyridines as inhibitors of FAK

The present invention provides thiazole sulfonamide and oxazole sulfonamide compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.

Benzene sulfonamide thiazole and oxazole compounds

Deuterated forms of N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide and pharmaceutical compositions containing the same.

Deuterated benzene sulfonamide thiazole compounds

Novel substituted 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.

2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy

2,4,5-Trisubstituted pyrimidine compounds

Novel substituted pyrimido[4,5-d]pyrimidin-2-one compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.

Tetrasubstituted pyrimidine compounds as chemical intermediates

The present invention relates to a compound represented by Formula (I): and pharmaceutically acceptable salts. Compounds of the present invention inhibit Aurora kinase, making them especially suitable for the treatment of a number of diseases, including solid tumor cancers and hematological cancers.

Azaindole inhibitors of aurora kinases

The present invention is directed to novel compounds of Formula (I) for use in the treatment of diseases in a mammal, in which inappropriate, excessive or undesirable angiogenesis has occurred and/or where excessive Tie2 receptor activity has occurred.

Furo- and thienopyrimidine derivatives, which are useful as TIE-2 and/or VEGFR-2 inhibitors are described herein. The described invention also includes methods of making such furo- and thienopyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.

4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof

Growing community of inventors

Wayne, PA, United States of America

Jerry Leroy Adams